1 US Department of Health and Human Services. Agency for Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma. Rockville (MD): The Agency; 1993. Clinical Practice Guideline No.1. AHCPR Publication No. 92-0023. p.107.

2 Registrar General for Scotland. Annual Report, 1997. Edinburgh: General Register Office for Scotland; 1997. [section 1.2] [section 1.4]

3 Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end stage renal replacement treatment. BMJ 1990; 301: 897-900.

4 Khan IH, Catto GR, Edward N, MacLeod AM. Chronic renal failure: factors influencing nephrology referral. QJM 1994; 87: 559-64.

5 Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-52.

6 Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.

7 Moderately elevated blood pressure. A report from SBU, The Swedish Council on Technology Assessment in Health Care. J Intern Med 1995; 238 (Suppl 737): 1-225.

8 Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 1996; 10: 1-8. [section 1.2] [section 1.5]

9 Dickerson JE, Brown MJ. Influence of age on general practitioners' definition and treatment of hypertension. BMJ 1995; 310: 574.

10 Dickerson JE, Garratt CJ, Brown MJ. Management of hypertension in general practice: agreements with and variations from the British Hypertension Society guidelines. J Hum Hypertens 1995; 9: 835-9.

11 Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304: 405-12. [section 1] [section 5.2] [section 5.2.1] [section 5.2.2] [section 6.2] [section 6.4]

12 Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103-9. [section 1.2] [section 1.3] [section 1.5] [section 4]

13 Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5. [section 1.2] [section 1.5] [section 5.2] [section 5.2.2] [section 6.2] [section 6.4] [section 6.6]

14 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64. [section 1.2] [section 1.5] [section 4.1] [section 4.3] [section 5.2] [section 5.2.3] [section 6.4]

15 Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64. [section 1.2] [section 1.5] [section 4] [section 5.2] [section 5.2.2] [section 6.2] [section 6.4] [section 6.6]

16 Kostis JB, Davis BR, Cutler J, Grimm RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278: 212-6. [section 1.2] [section 1.5]

17 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62. [section 1.2] [section 1.5]

18 1999 World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999: 17: 151-83. [section 1.2] [section 1.3] [section 3] [section 4] [Table 5-7] [section 5] [Figure 6]

19 The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46. [section 1] [section 2] [section 3]

20 Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R, on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (suppl 2): S1-S29. [section 1] [section 3] [section 4.2.1] [section 4.2.2] [section 5]

21 Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92. [section 1] [section 2] [section 3] [section 4.2] [section 4.4] [section 5.3.3] [section 5.4]

22 Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355-62. [section 1] [section 4]

23 Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med 1995; 4: 943-9. [section 1] [section 4]

24 Holme I, Ekelund LG, Hjermann I, Leren P. Quality-adjusted meta-analysis of the hypertension/coronary dilemma. Am J Hypertens 1994; 7: 703-12. [section 1] [section 4]

25 Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1990; 8: 393-405.

26 Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346: 1647-53.

27 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.

28 Scottish Office Department of Health. Scotland's Health: Scottish health survey 1995. Edinburgh: Stationery Office, 1997.

29 Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results from the thrid National Health and Nutrition Examination Survey, 1988-1991. Hyptertension 1995; 25: 305-13.

30 Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers MP, Franco LJ, et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension 1989; 14: 238-46.

31 Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens 1995; 13: 571-9.

32 Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-81.

33 Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly. Implications and generalizabity of randomized trials. JAMA 1994; 272: 1932-8.

34 Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995; 7: 242-50.

35 Hart JT. Semicontinuous screening of a whole community for hypertension. Lancet 1970; 2: 223-6.

36 Barber JH, Beevers DG, Fife R, Hawthorne VM, McKenzie HM, Sinclair RG, et al. Blood-pressure screening and supervision in general practice. BMJ 1979; 1: 843-6.

37 Coope J. A screening clinic for hypertension in general practice. J R Coll Gen Pract 1974; 24: 161-6.

38 Mayhew SR. Hypertension screening in general practice. Report on behalf of the General Practitioner Hypertension Study Group. J R Coll Gen Pract 1983; 33: 434-7.

39 Adorian D, Silverberg DS, Wamoscher Z, Tomer D. Use of management-by-objective for the case finding and treatment of hypertension. J R Coll Gen Pract 1986; 36: 17-8.

40 Holmen J, Forsen L, Hjort PF, Midthjell K, Waaler HT, Bjorndal A. Detecting hypertension: screening versus case finding in Norway. BMJ 1991; 302: 219-22.

41 O'Brien E, Petrie JC, Littler WA, de Swiet M, Padfield PL, Dillon MJ, et al. Blood pressure measurement. Recommendations of the British Hypertension Society. London: BMJ Books; 1997.

42 Thijs L, Staessen JA, Celis H, de Gaudemaris R, Imai Y, Julius S, et al. Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Int Med 1998; 158: 481-8.

43 Staessen JA, Bieniaszewski L, O'Brien ET, Fagard R. Special feature: what is a normal blood pressure in ambulatory monitoring? Nephrol Dial Transplantation 1996; 11:241-5

44 Webster J, Petrie JC, Jeffers TA, Lovell HG. Accelerated hypertension - patterns of mortality and clinical factors affecting outcome in treated patients. QJM 1993; 86: 485-93.

45 Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615.

46 Peto R, Collins R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell Scientific, 1994. pp. 1156-64.

47 Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761-7.

48 Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Int Med 2000; 160: 1085-9

49 Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100: 354-60.

50 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. NZ Med J 1996; 109: 224-31. [section 3] [section 4]

51 Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.

52 Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71.

53 Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield Table. Lancet 1996; 348: 387-8.

54 Haq IU, Jackson PR, Yeo WW, Ramsay LE. A comparison of methods for targeting CHD risk for primary prevention. Heart 1997; 77(Suppl 1): 36. [abstract]

55 Scottish Intercollegiate Guidelines Network (SIGN). Lipids and the primary prevention of coronary heart disease. A national clinical guideline. Edinburgh: SIGN, 1999. (SIGN publication no.40). [section 4] [section 5.1.6] [section 5.3.2]

56 Isles CG, Ritchie LD, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: a comparison of three scoring methods. BMJ 2000; 320: 690-1.

57 Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al.. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-62. [section 4] [section 5.2.3] [section 5.3.1] [section 6.1] [section 6.2]

58 Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.

59 Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98.

60 MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-71.

61 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13. [section 4] [section 6]

62 Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-Shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34:1181-5.

63 Stamler J, Caggiula AW, Grandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr 1997; 65(suppl1): 338S-365S. [section 5.1] [section 5.1.2]

64 Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med 1998; 20: 441-8.

65 Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997; 314: 1666-74.

66 Brand MB, Mulrow CD, Chiquette E, Angel L, Cornel J, Summerbell C, Anagnostelis B, Grimm R. Dieting to control body weight for controlling hypertension in adults (Cochrane review). In: The Cochrane library Issue 3 1999. Oxford: Update Software

67 Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279: 839-46. [section 5.1] [section 5.1.3]

68 Neaton JD, Grimm RH, Prineas RJ, Stamler J, Gandits GA, Elmer PJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-24. [section 5.1.1] [section 5.2.6]

69 Puddey IB, Parker M, Beilen LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992; 20: 533-41.

70 Gill JS, Shipley MJ, Tsementzis SA, Hornby RS, Gill SK, Hitchcock ER, et al. Alcohol consumption-a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med 1991; 90: 489-97.

71 Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomised controlled trials. JAMA 1996; 275: 1590-7.

72 Appel LJ, Moore TJ, Obarzanek E,Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.

73 Braith RW, Pollock ML, Lowenthal DT, Graves JE, Limacher MC. Moderate- and high-intensity exercise lowers blood pressure in normotensive subjects 60 to 79 years of age. Am J Cardiol 1994; 73: 1124-8.5

74 Kokkinos PF, Narayan P, Colleran JA, Pittaras A, Notargiacomo A, Reda D, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med 1995; 333: 1462-7.

75 Paffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-45.

76 Scottish Intercollegiate Guidelines Network (SIGN). Secondary prevention of coronary heart disease following myocardial infarction. A national clinical guideline. Edinburgh: SIGN, 2000. (SIGN publication no.41). [section 5.1.6] [section 5.3.2]

77 Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54. [section 5.2] [section 5.2.1] [section 6.2] [section 6.6]

78 Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6. [section 5.2] [section 5.2.3] [section 5.2.4]

79 Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-7. [section 5.2.1] [section 5.2.2]

80 Grimm RH Jr, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638-48.

81 Carlsen JE, Kober L, Torp-Pedersen, C Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975-8.

82 Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-7.

83 Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-21. [section 5.2.2] [section 5.2.3]

84 Liu L, Wang JG, Gong L, Liu G, Staessen JA.. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-9.

85 Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-45.

86 Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.

87 Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.

88 Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7.

89 Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-5.

90 Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hypertens 1997; 15: 105-15.

91 Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992: 327: 669-77.

92 Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-20. [section 5] [section 6]

93 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Death from Cardiovascular Causes, Myocardial Infarction, and Stroke in High-Risk Patients. NEJM 2000 (in press) [http://www.nejm.org/content/yusuf/1.asp]

94 Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.

95 Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 747-52.

96 Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT. Lancet 2000; 355: 863-4.

97 McInnes G. Blood pressure control. Aspects of modern management. London, Current Medical Literature, 1999. p31.

98 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41.

99 Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotic therapy. Edinburgh: SIGN 1999. (SIGN publication no. 36).

100 Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther 1994; 16: 316-26.

101 Mallion JM, Baguet JP, Siche JP, Tremel F, de Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens Suppl1998; 16: S75-9.

102 Shimp LA, Ascione FJ, Glazer HM, Atwood BF. Potential medication-related problems in noninstitutionalized elderly. Drug Intell Clin Pharm 1985; 19: 766-72.

103 Walker R. Stability of medicinal products in compliance devices. Pharm J 1992; 248: 124-6.

104 Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens 1993; 7: 515-8.

105 Yasin S. Detecting and improving compliance. Is concordance the solution? Aus Fam Physician 1998; 27: 255-60.

106 Kjellgren KI, Ahlner J, Saljo R. Taking antihypertensive medication - controlling or co-operating with patients? Int J Cardiol 1995; 47: 257-68.

107 Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996; 36: 443-51.

108 Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821-7.

109 Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.

110 Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-9. [section 6.1.1] [section 6.1.2]

111 Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-92.

112 Treating mild hypertension: agreement from the large trials. Report of the British Hypertension Society Working Party. BMJ 1989; 298: 694-8.

113 Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.

114 Tattie P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo F. Results of the Fosinopril Amlodipine Cardiovascular Events Trial in hypertensive patients with non-insulin dependent diabetes (NIDDM). Circulation 1997; 96 (Suppl 1): 1-764.

115 Tuomilehto J, Rastenyte D, Birkenhager W, Thijs L, Antikainen R, Bulpitt CJ, et al for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockade on older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.

116 Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-17.

117 Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11:319-25.

118 Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-50. [section 6.1.2] [section 6.3.2]

119 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62.

120 Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalburninuria. Lancet 1995; 346: 1080-4.

121 Parving HH. Initiation and progression of diabetic nephropathy. N Eng J Med 1996; 335: 1682-3.

122 Flack JM, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92: 2437-45.

123 Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-71.

124 Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69.

125 Boden WE, van Gilst WH, Scheldewaert RG, Starkey KT, Carlier MF, Julian DG, et al for the Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Lancet 2000; 355: 1751-56.

126 The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol 1996; 12: 127-37.

127 Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.

128 Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997; 18: 560-5.

129 Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and treatment of heart failure due to left ventricular systolic dysfunction: a national clinical guideline. Edinburgh: SIGN 1999. (SIGN publication no. 35).

130 Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.

131 Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345: 749-51.

132 Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-4.

133 Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992; 327: 543-7.

134 Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997; 17: 67-76. [section 6.3.1] [section 6.3.2]

135 1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group. Arch Intern Med 1996; 156: 1938-47.

136 Bonelli FS, McKusick MA, Textor SC, Kos PB, Stanson AW, Johnson CM, et al. Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995; 70: 1041-52.

137 Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al. Randomised comparison of percutaneuos angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12: 329-35.

138 Isles CG, Robertson S, Hill D. Management of renovascular disease: a review of renal artery stenting in ten studies. QJM 1999; 92: 159-167.

139 Brown MA, Whitworth JA. Hypertension in human renal disease. J Hypertens 1992; 10: 701-12.

140 British Medical Association, Royal Pharmaceutical Association of Great Britain. British National Formulary, March 1999. London: BMA; 1999. p.615.

141 Giatras I, Lau J, Levey AS. Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta analysis of randomised trials. Angiotensin-Converting-Enzyme-Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-45.

142 Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.

143 Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997; 349: 1857-63.

144 Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-51.

145 Schrader J, Rothemeyer M, Luders S, Kollmann K. Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Basic Res Cardiol 1998; 93 Suppl 2:69-78

146 Rodgers A, Neal B, MacMahon S. The effects of blood pressure lowering in individuals with cerebrovascular disease: an overview of randomised controlled trials. Neurol Rev Int 1997; 2: 12-15.

147 Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive interventional trials) Project Collaborators. Stroke 1997; 28: 2557-62.

148 Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. J Hypertens 1996; 14: S41-6.

149 Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.

150 Starr JM, Whalley LJ. Senile hypertension and cognitive impairment: an overview. J Hypertens 1992; 10: S31-42.

151 Guo ZM, Viitanen M, Fratiglioni L, Winblad B. Blood pressure and dementia in the elderly:epidemiologic perspectives. Biomed Pharmacother 1997; 51: 68-73.

152 Lis CG, Gaviria M. Vascular dementia, hypertension, and the brain. Neurol Res 1997; 19: 471-80.

153 Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension. Dementia 1994; 5: 174-6.

154 Philips SJ, Whisnant JP. Hypertension and the brain. The National High Blood Pressure Education Programme. Arch Intern Med 1992; 152: 938-45.

155 Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.

156 Gueyffier F, Bulpitt C, Boissel J-P, Schron E, Ekbom T, Fagard R, et al for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793-6.

157 Bulpitt CJ, Fletcher AE, Amery A, Coope J, Evans JG, Lightowlers S, et al. The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials. Drugs Aging 1994; 5: 171-83.

158 Gambassi G, Lapane K, Sgadari A, Landi F, Carbonin P, Hume A, et al. Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. SAGE (Systematic Assessment of Geriatric Drug Use via Epidemiology) Study Group. Arch Intern Med 1998; 158: 2377-85